Bortezomib (Velcade?) in the treatment of multiple myeloma
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates improved outcomes in multiple myeloma using bortezomib, indicating its effectiveness in treatment.
Key Points
- To evaluate the effectiveness of bortezomib in treating multiple myeloma and its impact on survival rates.
- Analyzed the effects of bortezomib in relapsed multiple myeloma patients post transplant and in those unsuitable for transplant.
- Compared bortezomib treatment with dexamethasone alone in terms of progression-free and overall survival.
- Reported synergistic effects with dexamethasone and other chemotherapeutic agents.
- Bortezomib treatment resulted in over 50% response rates in the relapsed setting.
- Response rates of 80%-90% were observed when bortezomib was combined with other agents in frontline therapy.
- Progression-free and overall survival rates significantly improved compared to dexamethasone alone.
Cite This Study
Field-Smith et al. (2006) studied this question.